Amended and Restated Exclusive IP Marketing AgreementExclusive Ip Marketing Agreement • February 21st, 2019 • Enzon Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
This Amended and Restated Exclusive IP Marketing Agreement (“Agreement”) is made and entered into as of June 28, 2004 (the “Amendment Date”) and is hereby made effective as of April 9, 2002 (the “Effective Date”), by and between Micromet AG, having its principal offices at Staffelseestrasse 2, 81477 Munich, Germany (“Micromet”), and Enzon Pharmaceuticals, Inc., having its principal offices at 685 Route 202/206, Bridgewater, New Jersey 08807, USA (“Enzon”). Micromet and Enzon each may be referred to herein individually as a “Party,” or collectively as the “Parties.”
SERVIER IP UK LIMITED LETTERHEAD]Asset Purchase Agreement • February 21st, 2019 • Enzon Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Delaware
Reference is made to that certain Asset Purchase Agreement, dated as of November 9, 2009, by and between Klee Pharmaceuticals, Inc. (“Klee”), Defiante Farmaceutica, S.A. (“Defiante”), and Sigma-Tan Finanziaria S.p.A. (solely for the purpose of Section 6.4, Section 7.8(a), Section 7.8(e) and Section 12.17 thereof), on the one hand, and Enzon Pharmaceuticals, Inc. (“Enzon”), on the other hand (the “APA”). Capitalized terms used in this letter agreement without definition shall have the meanings given to them in the APA.
